Lilly refers 200-plus retatrutide sellers to regulators as it sues six
Lilly wants agencies and licensing boards to act against sellers of its unapproved weight-loss drug, which is not cleared for human use anywhere and is still months from an FDA filing.
Eli Lilly says it has handed regulators and law enforcement the names of more than 200 people and businesses that sell or advertise "research-use-only" retatrutide, the experimental weight-loss drug the company is still testing [1][2]. The referrals were disclosed alongside six lawsuits Lilly filed on August 12, 2026 [2].
The suits name compounding pharmacies, medical spas and online sellers that Lilly accuses of illegally selling versions of the molecule [2]. Referrals went to the FDA, the Justice Department, state attorneys general, law enforcement and professional licensing boards [2]. Lilly also says it has flagged more than 14,000 websites, advertisements, social media posts and product listings it calls unlawful marketing of retatrutide, spread across more than 100 countries [2].
No regulatory agency anywhere has approved a retatrutide medicine for human use, and the molecule is in phase 3 trials for obesity, Type 2 diabetes and related conditions [2]. In trials it produced average weight loss of 28.3 percent over 80 weeks, and Lilly has said it plans to file for FDA approval in early 2027 [1][2].
Products sold as research-use-only retatrutide are not the drug used in those trials. What such products contain, and whether they are tested at all, has not been reported.
The referral figure is many times larger than the six-company docket, which suggests Lilly is treating the gray market as an enforcement matter and not only a civil one: referrals ask agencies and licensing boards to act on their own. Whether any of the referred parties has been charged, fined or disciplined has not been reported.
A second front is a fight over how retatrutide is classified. Lilly wants the FDA to call it a biologic rather than a conventional drug; biologics cannot be compounded and receive 12 years of statutory exclusivity against five years for new drugs [1]. The FDA defines a protein as an alpha amino acid polymer with a defined sequence larger than 40 amino acids [1]. Lilly counted 39 amino acids in retatrutide's backbone plus two bonded on, for 41; the FDA said no in March 2024 [1]. Lilly sued in September 2024, and in 2025 Judge Tanya Walton Pratt agreed the molecule missed the strict protein definition but found the agency acted capriciously in how it judged what is "analogous" to a protein, sending the question back to the FDA [1]. Lilly appealed to the 7th Circuit on February 17, 2026, arguing that the statutory deadline for a decision had run out; the FDA says the clock did not restart when a court vacated its earlier ruling [1]. The Outsourcing Facilities Association, which represents compounding pharmacies, sided with the FDA and called Lilly's appeal a "money grab" [1].
Why it matters for patients
Price is the engine behind the market Lilly is trying to shut down. Compounded GLP-1 drugs sell for about $150 to $200 a month, against $299 to $449 in self-pay for the highest doses of the brand-name products [1]. Novo Nordisk's chief executive has estimated 1.5 million patients get tirzepatide or semaglutide from compounders [1]. Those numbers cover medicines already on the market; retatrutide is not one of them.
If retatrutide is designated a biologic, compounding it would be off the table, which the court fight suggests would mean less price competition and higher prices for longer [1]. If Lilly loses, the ruling raises the possibility that the exclusivity drugmakers count on may be slower and costlier to defend [1].
For now, the only route to authentic retatrutide is Lilly's expanded access program, which the company says may supply the drug before approval to a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial [2]. How many people it will accept, and when, has not been disclosed.
What happens next
The 7th Circuit hears oral arguments in Eli Lilly and Company v. Robert F. Kennedy, Jr. on September 24, 2026 [1]. Lilly has said it intends to submit retatrutide for FDA approval in early 2027 [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.